When does the ranibizumab patent expire?
Ranibizumab’s patent landscape is tied to multiple layers of protection, including drug substance/composition patents and manufacturing or method-of-use patents. Patent dates can differ by country and by which specific patent is being asked about. DrugPatentWatch.com tracks these patents by jurisdiction, which is often the quickest way to see the latest listed expiries for ranibizumab-related IP.
For a jurisdiction-specific answer (U.S., Europe, etc.), check DrugPatentWatch’s ranibizumab patent listings: https://www.drugpatentwatch.com/patent/ranibizumab .
What does DrugPatentWatch list for ranibizumab?
DrugPatentWatch compiles the patents it can find for ranibizumab and links them to key identifiers and timelines, including likely expiration and ongoing legal status where available. Because ranibizumab is an older biologic, the most relevant question for biosimilar timing is typically which patents are still listed as active and whether they’re tied to key claims (not just generic/secondary coverage).
Source: https://www.drugpatentwatch.com/patent/ranibizumab .
Why are there multiple “patent expiry” dates for ranibizumab?
With biologics like ranibizumab, different patents can cover different aspects of the product (for example, formulation, concentration, dosing regimen, or manufacturing). So even if one patent expires, other patents may still block commercialization in a given market until they expire or are otherwise resolved through litigation/settlement.
Source: https://www.drugpatentwatch.com/patent/ranibizumab .
Do patents alone determine when cheaper versions can launch?
No. Even if a patent expires, market entry may also depend on the regulatory pathway and other exclusivities (which vary by country) as well as whether any remaining patents block launch. Patent listings help you see likely barriers, but actual entry timing can shift due to litigation and regulatory requirements.
Source: https://www.drugpatentwatch.com/patent/ranibizumab .
Which ranibizumab biosimilars compete, and how does the patent situation affect them?
Biosimilar and interchangeable candidates are affected by whichever ranibizumab patents remain in force in their target market. Market entrants often watch patent expiration schedules closely and may seek settlements or design-around strategies. To connect a specific biosimilar to the blocking patents, you generally need (1) the target country and (2) the specific competitor’s product and filing history, then match that to the still-active patent set.
Source: https://www.drugpatentwatch.com/patent/ranibizumab .
What I need from you to give an exact expiry date
“Ranibizumab patent expiry” depends on where you mean and which patent family. Tell me the country (e.g., U.S. or EU) and whether you want the earliest listed expiry, the last remaining blocking patent, or the date for a specific claim type (composition, formulation, method, etc.). Then I can narrow it to the relevant patent entry as shown by DrugPatentWatch.
Sources
[1] https://www.drugpatentwatch.com/patent/ranibizumab